Ernæring og væskebehandling til pasienter med ikke-kurabel kreftsykdom
- 1.
Stasser F. Patophysiology of the anorexia/cachexia syndrome. I: Doyle D, Hanks G, Cherny N et al, red. Oxford textbook of palliative medicine. 3. utg. Oxford: Oxford University Press, 2004: 520 – 33.
- 2.
Dewys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491 – 7.
- 3.
Bosaeus I, Daneryd P, Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 2002; 132: 3465S–6.
- 4.
Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol 2003; 1: 159 – 68.
- 5.
Acharyya S, Ladner KJ, Nelsen LL et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114: 370 – 8.
- 6.
Klein S, Koretz RL. Nutrition support in patients with cancer: what do the data really show? Nutr Clin Pract 1994; 9: 91 – 100.
- 7.
Strasser F, Bruera E. Update on anorexia and cachexia. Hematol Oncol Clin North Am 2002; 16: 589 – 617.
- 8.
Ovesen l, Allingstrup L, Hannibal J et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993; 11: 2043 – 9.
- 9.
MacDonald N. Anorexia-cachexia syndrome. Eur J Pall Care 2005; 12 (suppl): 8 – 14.
- 10.
The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66 – 72.
- 11.
Lundholm K, Daneryd P, Bosaues I et al. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism and function. Cancer 2004; 100: 1967 – 76.
- 12.
Bozzetti F, Amadori D, Bruera E et al. Guidelines on artificial nutrition versus hydration in terminal cancer patients. European Association for Palliative Care. Nutrition 1996; 12: 163 – 7.
- 13.
Bruera E, Kuehn N, Miller M et al. The Edmonton Symptom Assessment System (ESAS): a simple method. J Palliat Care 1991; 7: 6 – 9.
- 14.
Thoresen L, Fjelstad I, Krogstad K et al. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med 2002; 16: 33 – 42.
- 15.
Bruera E, Belzile M, Neumann C et al. A double-blind, crossover study of controlled release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Sympt Manage 2000; 19: 427 – 35.
- 16.
Bruera E, Roca E, Cedaro L et al. Action of oral metylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69: 751 – 4.
- 17.
Lopirinzi C, Kugler JW, Mailliard JA et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17: 3299 – 306.
- 18.
Thomas DA, Kantarjian H. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000; 12: 564 – 73.
- 19.
Tisdale MJ. Protein loss in cancer cachexia. Science 2000; 289: 2293 – 4.
- 20.
Jatoi A, Rowland K, Loprinzi CL et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22: 2469 – 76.
- 21.
Jatoi A, Windschitl H, Loprinzi C et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-assosiated anorexia: a North Central Cancer Treatment Group Study. J Clin Oncol 2002; 20: 567 – 73.
- 22.
Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003; 11: 137 – 43.
- 23.
Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004; 64: 725 – 50.
- 24.
Agteresch HJ, Rietveld T, Kerkhofs LG et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002; 20: 371 – 8.
- 25.
May PE, Barber A, D’Olimpio JT et al. Reversal of cancer-related wasting using oral supplementation with a combination of -hydroxy--metylbutyrate, arginine and glutamine. Am J Surg 2002; 183: 471 – 9.
- 26.
Lundholm K, Gelin J, Hyltander A et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 52: 5602 – 6.
- 27.
MacDonald N. Is there evidence for earlier intervention in cancer-associated weight-loss? J Support Oncol 2003; 1: 279 – 86.
- 28.
McCann RM, Hall WJ, Groth-Juncker A. Comfort care for the terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272: 1263 – 6.
- 29.
Husebø S. Væskebehandling av pasienter i terminalfasen. Omsorg 1997; 3: 26 – 30.
- 30.
Ellershaw JE, Sutcliffe JM, Saunders CM. Dehydration and the dying patient. J Pain Symptom Manage 1995; 10: 192 – 7.
- 31.
Musgrave CF, Bartle N, Opstad J. The sensation of thirst in dying patients receiving iv. hydration. J Palliat Care 1995; 11: 17 – 21.
- 32.
Bruera E, Franco JJ, Maltoni M et al. Changing pattern of agitated impaired status in patients with advanced cancer: association with cognitive monitoring, hydration and opioid rotation. J Pain Symptom Manage 1995; 10: 287 – 91.
- 33.
Musgrave CF. Fluid retention and intravenous in the dying. J Pain Symptom Manage 1995; 10: 643 – 6.